StockpollyBeta
Get App
Popularity #1,058
NVS · NYSE · Drug Manufacturers - General

Novartis (ADR) (NVS)

Develops innovative medicines across four therapeutic areas and multiple advanced technology platforms.

$141.28
After hours+0.01 (+0.01%)
At close$141.27(+0.21%)

  1. NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

    Zacks Investment Research

  2. Novartis halts ALS drug development after mid-stage trial failure

    Reuters

  3. Legend Biotech taps Novartis veteran Zhang as CEO

    Reuters

  4. Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

    WSJ

  5. Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

    The Motley Fool

  6. Novartis: More Pain on the Way?

    Barrons

  7. Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning

    GuruFocus

  8. Focus: Novartis investors turn spotlight on M&A after trial setbacks

    ReutersClinical

  9. Major Novartis shareholder calls for board shake-up after drug trial setbacks

    ReutersM&A

  10. Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

    Zacks Investment ResearchClinical

  11. Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

    BenzingaMarket move

  12. Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

    ReutersMarket move

  13. Novartis Trial Failure Sparks Biopharma Options Frenzy

    Schaeffers ResearchMarket move

  14. Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial

    Proactive Investors

  15. Novartis (NVS) Faces Setbacks in Clinical Trials, Impacting Pipeline and Stock Value

    GuruFocusClinical

  16. Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday

    InvestopediaMarket move

  17. Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed

    Seeking AlphaOther

  18. Novartis's failed trial for cholesterol drug leads to broad biopharma selloff

    Market WatchMarket move

  19. 'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat

    CNBCMacro

  20. Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

    BenzingaClinical